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From June, 1980, to August, 1983, 131I MIBG scintiscans 
were performed in 353 patients with suspected pheo- 
chromocytomas. Extra-adrenal pheochromocytomas were 
identified in 15 of 18 patients who at operation were proven 
to have such tumors and normal adrenal glands. Conven- 
tional localization studies, often repeated, had failed to lo- 
calize these tumors in nearly all Cases. Nine of the extra- 
adrenal pheochromocytomas were found within the middle 
mediastinum. This group of unique tumors required fur- 
ther specialized localization studies with augmented com- 
puted tomography (CT) scans for specific anatomical de- 
lineation. These complementary studies allowed for pre- 
cise planning of surgical excision of the tumors, which 
required cardiopulmonary bypass in some patients. Extra- 
adrenal pheochromocytomas were identified in a family 
with no other endocrinopathies. The tumors in 3 patients 
from 3 different generations all were perirenal and in- 
volved the vena cava. 
131I MIBG scintiscans detected metastatic lesions in 40 
patients with malignant pheochromocytomas. Metastases 
were not readily demonstrated in 4 patients. The diagnosis 
of malignant and metastatic pheochromocytoma was first 
made by the scintiscan findings in 5 patients. 131I MIBG 
scans were not false-positive in any cases and were false- 
negative in 10.5% of 95 patients proven to have pheo- 
chromocytomas by biochemical evidence or operation. 
Ten patients have been treated for malignant pheo- 
chromocytomas with therapeutic doses of 131I MIBG. Five 
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patients have had objective responses with diminution in 
size of metastases or primary malignant tumor and a de- 
crease in the secretion of catecholamines. 
This agent has been found to be of great value in detect- 
ing pheochromocytomas that often have defied all other 
means of localization. 131I MIBG concentrates in most ma- 
lignant pheochromocytomas, and preliminary results sug- 
gest that it will be very useful in the trealment of this disease. 
The diagnosis of  pheochromocy toma  is frequently 
simpler than the anatomical localization of the tu- 
mor. Elevations in plasma and/or urinary cate- 
cholamine and their metabolites, coupled with a 
characteristic clinical picture can usually establish 
the diagnosis. The tumor localization, however,  
particularly when there is malignant, extra-adre- 
nal, or bilateral disease, may be very difficult. Ap- 
proximately 10% of pheochromocytomas  arise 
from chromaffin tissue anywhere  from the base of 
the skull to the bladder. Furthermore,  some pheo- 
chromocytomas  may be multiple, in extra-adrenal 
locations, or concurrently intra-adrenal and extra- 
adrenal. Third-generation computer  assisted tomog- 
raphy is extremely accurate in localizing intra-ad- 
renal lesions, but is not very helpful for identifying 
extra-adrenal or metastatic pheochromocytomas .  
Until recently, no available modality could provide 
both an anatomical and functional documentat ion 
of the tumor prior to surgical intervention. The syn- 
thesis of 131I meta-iodobenzylguanidine (131I 
MIBG) has made it possible to obtain scintigraphic 
images of pheochromocytomas  and hyperplastic 
chromaffin tissue. This compound,  a guanidine ana- 
logue with molecular structure similar to that of 
norepinephrine, was found by Wieland et al. [1] to 
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have a strong affinity for adrenergic tissue. For the 
past 3 years, 13~I MIBG scintiscans have been used 
at The University of Michigan for the localization 
of pheochromocytomas and for screening patients 
with multiple endocrine neoplasia type II and other 
neuroectodermal dysplasias. 13~I MIBG has also 
been used in the management of inoperable and 
metastatic pheochromocytomas. This report de- 
scribes our experience with this agent. 
Methods and Materials 
Patient Populations 
During the 3-year period from August 1980, to Au- 
gust, 1983, a total of 353 patients with suspected pheo- 
chromocytomas was studied at The University of 
Michigan Medical Center. Nearly a third of the pa- 
tients had the diagnosis established by biochemical 
studies. These patients were referred for localiza- 
tion and possible treatment of their pheochromo- 
cytomas. Many other patients had hypertension 
that was labile, difficult to control, or paroxysmal, 
and underwent scintiscans because to do so expe- 
dited their pheochromocytoma evaluation when 
they had been treated with a drug such as alpha- 
methyldopa that interferes with biochemical test- 
ing. Some patients had suspicious but not diagnos- 
tic catecholamine elevations in either plasma or 
urine. Other patients with proven MEN IIa or Iib 
syndromes, without hypertension or biochemical 
evidence of pheochromocytoma, underwent scin- 
tiscans with 131I MIBG as part of a screening pro- 
tocol. Although 131I MIBG scans were used primar- 
ily for localization, in a few cases the scan was the 
first diagnostic proof that a pheochromocytoma 
was present. 
The 95 patients with proven pheochromocyto- 
mas ranged in age from 9 to 69 years. Fifty-one 
were males and 44 were females. With the excep- 
tion of 2 MEN IIa patients who were asymptomat- 
ic except for episodes of palpitations and anxiety, 
all were hypertensive. There were 18 patients with 
familial disease associated with pheochromo- 
cytomas including 8 with MEN IIa, 3 with MEN 
IIb, 5 with neurofibromatosis, 1 with von Hippel- 
Lindau, and 1 with Carney's triad (pheochromo- 
cytoma, gastric leiomyoblastoma, and pulmonary 
chondroma) [3]. 
All patients with proven pheochromocytomas 
had at least 1 urinary catecholamine or catechola- 
mine metabolite level within the diagnostic range. 
Many patients also had diagnostic elevations in 
their plasma catecholamines as well. In addition to 
undergoing the 1311 MIBG scan, patients were 
screened for pheochromocytoma by CT scanning. 
Technique for Scanning with 1sli MIBG 
131I MIBG was synthesized and prepared for intra- 
venous injection as previously described [1, 2]. 
Lugol's iodine, 30 rag, was given orally for 5 days 
beginning 24 hours before the injection of ~3~I 
MIBG in order to block uptake of 1311 by the thy- 
roid gland. A dose of 0.5 mCi per 1.7 m 2 of body 
surface area (not to exceed a total dose of 0.5 mCi) 
was injected intravenously over 10-20 seconds on 
the day prior to the first scan. Scanning was per- 
formed at 24, 48, and 72 hours after injection. In 
cases in which anatomic orientation was uncertain, 
(99mTc) pentetic acid or (99mTc) diethylene triamine- 
pentacetic acid was also administered to visualize 
the kidney. 
Administration of lsli MIBG for the Treatment 
of Metastatic or Inoperable Malignant 
Pheochromocytomas 
Ten patients with unresectable metastases or in- 
operable primary tumors that showed uptake by 
13JI MIBG scintography were administered thera- 
peutic doses of this agent. Early in the experience 
with therapy, approximately 100 mCi was given as 
the initial dose. During the last year. however, pa- 
tients have been given 200 mCi as a initial dose. 
The majority of patients have been given 2 or 3 
doses with maximum of 600 mCi When adminis- 
tered therapeutically, 131I MIBG was given as a 100 
mCi dose of 131I on 5 mg of MIBG and infused at 
the rate of 3 mg/30 min. intravenously. I1 was cal- 
culated that each dose of 100 mCi of MIBG would 
deliver approximately 3.400 rad. A therapeutic 
dose is now considered to be a total of 300 mCi or 
10.200 rad delivered to the tumor. 
Results 
Isli MIBG Localization 
Of 95 patients proven to have pheochromocytomas 
by operation or consistently diagnostic biochemi- 
cal determinations. 85 were visualized by 131I 
MIBG scintigraphy (Table IL The false-negative 
rate was. therefore. 10.5%. There were no false- 
positive studies. Eighteen of 19 patients with intra- 
adrenal sporadic pheochromocytomas had localiz- 
ing scintiscans. In the single false-negative case, a 
51-year-old man had a large easily identifiable left 
adrenal pheochromocytoma that was cystic on CT 
scanning. The excised lesion was a fluid-filled 
neoplastic cyst with a maximum wall thickness of 
0.5 cm. It is possible that cystic degeneration of 
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Table 1. 131I MIBG detection of pheochromocytoma or 
metastases. 
No. shown (No. proven) 
with 13q MIBG 
Intra-adrenal (sporadic) 18 (19) 
Extra-adrenal 15 (18) 
Malignant (sporadic) 34 (38) 
Familial 18 (18) 
Bilateral 12 
Malignant 6 
Total 85 (93)" 95% 
~Location of pheochromocytomas in 2 patients with 
biochemical proof, undetermined. 
this p h e o c h r o m o c y t o m a  was responsible for its fail- 
ure to take up 131I MIBG.  
Fifteen of  18 patients had extra-adrenal  pheo- 
ch romocy tomas  that were visualized by 131I MIBG 
scanning. Six of  these were in intra-abdominal  lo- 
cations. Five were periaortic and one was perire- 
nal. In 1 patient,  2 periaortic pheochromocy tomas  
were  visualized. This 30-year-old man had, 1 year  
previously,  undergone a left adrenalec tomy for an 
intra-adrenal pheochromocytoma.  Because of re- 
current  hypertension,  he was extensively studied 
for a possible extra-adrenal lesion. Plasma venous 
catecholamine levels, repeated abdominal and me- 
diastinal CT scans, and abdominal aor tography 
with selective studies failed to identify his tumor  
sites. An 1311 MIBG scan readily showed 2 tumors 
in the periaortic region as depicted in Fig. 1. 
Nine patients had pheochromocy tomas  found in 
the middle mediastinum. With 1 exception,  all were 
initially discovered after 1311 MIBG scintiscanning. 
In 1 case. a tumor  blush was initially seen as a re- 
sult of  coronary  angiography. Three of these pa- 
tients were males and 6 were females,  ranging in 
age from 18 to 61 years. Five tumors  were excised 
using cardiopulmonary  bypass.  In each of  these. 
the left atr ium was the site of origin of  the tumor.  
Three of the 5 patients are considered cured. One 
patient  died on the first postoperat ive day with dif- 
fuse intravascular  coagulation. One patient has per- 
sistent disease because  of skeletal metastases .  One 
tumor  was stripped f rom the atrium without the 
need for cardiopulmonary  bypass  and is cured. An- 
other  pat ient ' s  tumor  was in the aor t icopulmonary 
window and could be excised without difficulty. 
One patient with Carney ' s  syndrome has not under- 
gone operat ion for pheoch romocy toma  because  she 
has proven  liver metas tases  with gastric lei- 
omyoblas toma.  Another  patient is awaiting opera- 
tion. These  rare middle mediastinal pheochromo-  
cy tomas  have been reported in detail e lsewhere 
[3]. Ten of  18 extra-adrenal  pheochromocy t0mas  
proved  to be malignant. 
Fig. 1. A 30-year-old male patient with 2 extra-adrenal 
primary pheochromocytomas localized by 131I MIBG 
scan after other studies failed to show the tumors. 
Fig. 2. Liver metastases in a 27-year-old woman with 
MEN IIa demonstrated by 13q MIBG scan (left) and 
99mTc.sulfur colloid scan (right). 
There  were  44 patients with malignant pheo-  
ch romocy tomas  as determined by metas tases  in 
lymph nodes,  liver, lung, or bone.  In 18 of these,  
the pr imary tumor  was extra-adrenal .  In several  
cases the pr imary tumor  was identified as malig- 
nant because  metas tases  were d iscovered  by the 
608 World J. Surg. Vol. 8, No. 4, August 1984 
Fig. 3. A 131I MIBG scan of the pelvis showing the pri- 
mary pheochromocytoma periaortic focus (solid arrow) 
and a metastatic deposit in the left acetabulum (open ar- 
row). Normal bladder activity is outlined by small ar- 
rows. 
scintiscan (Fig. 2). Malignant pheochromocytomas 
were identified by scintiscanning in 40 cases. 
Thirty-four of these were malignant sporadic pheo- 
chromocytomas. In addition, pheochromocyt0mas 
in 6 patients with familial disease were malignant. 
Two were MEN IIa patients and both had liver 
metastases that were visualized. Four additional 
patients had malignant pheochromocytomas that 
did not appear with MIBG scanning. In 3 of these 
cases the metastases were in bone and had been 
previously treated with external irradiation. In 1 
patient, hepatic metastases did not appear al- 
though in several others they were easily identified. 
In addition to the false-negative scan in I patient 
with an intra-adrenal pheochromocytoma, 3 pa- 
tients, with surgically proven pheochromocytomas 
in the region of the right renal hilus, had negative 
131I MIBG scans. Two of these pheochromo- 
cytomas were localized by CT scans. Selective aor- 
tography localized the third lesion. These 3 pa- 
tients all had elevations of urinary catecholamine 
levels, diagnostic of pheochromocytoma. There 
were 4 patients with malignant disease whose 
metastases did not visualize. Two patients have 
persistently diagnostic levels O f catecholamines but 
these tumors have not as yet been localized by any 
study. 
Therapeutic Use of  1311 MIBG 
Thus far, 10 patients with metastatic pheochromo- 
cytomas or inoperable primary tumors have been 
treated with therapeutic doses of 131I MIBG. Five 
patients have shown objective responses as deter- 
mined by decrease in tumor size to less than 50% 
of the original volume and/or significant decrease in 
urinary catecholamine levels. The most dramatic 
response has been seen in a 62-year-old male pa- 
tient who had a large inoperable periaortic pheo- 
chromocytoma completely encircling his upper ab- 
dominal aorta and vena cava, extending from the 
diaphragm to the bifurcation of the aorta. This pa- 
tient had severe pain radiating to his scrotum, se- 
vere hypertension, and intractable angina. During 
an attempted resection at another hospital, he had 
had a cardiac arrest and myocardial infarction. 
During a 2-year period (!980-1982), he was given 3 
doses of 131I MIBG (500 mCi). His tumor size and 
urinary catecholamines have decreased to a third of 
pretreatment levels. In 1983 he underwent a suc- 
cessful triple coronary artery bypass without ad- 
renergic blockage at another hospital. He has no 
hypertension. 
D i s c u s s i o n  
1311 MIBG scintigraphy represents an important ad- 
vance m the diagnosis and treatment of pheochro- 
mocytoma. Until now. adrenal lesions, if large 
enough, could be documented with computed 
tomography or anglography, but their functional 
status could not be readily assessed without selec- 
tive plasma catecholamine sampling, which was 
often inaccurate. If a patient with the clinical and 
biochemical features of pheochromocytoma had an 
adrenal lesion on CT scan. it was presumed to be a 
pheochromocytoma. Preoperative assessment of 
metastatic involvement was difficult and frequently 
lesions in extra-adrenal sites were not visualized. 
In our series, the mean time interval from the di- 
agnosis of pheochromocytoma to the diagnosis or 
identification of metastatic disease was 9 years 
(range 0-33 years). Among patients with a history 
of pheochromocytoma, the duration of symptoms 
due to metastases was 3.7 years (range 0-18 years) 
before identification by the 131I MIBG scintiscan. 
Extra-adrenal metastatic lesions could be visu- 
alized in most cases. Until 131I MIBG became avail- 
able. the discovery of an intra-thoracic pheochro- 
mocytoma was a rare and reportable event. Until 
1980 only 24 cases of intra-thoracic pheochromo- 
cytomas were reported in the world literature [7]. 
In this series. 9 intra-pericardial lesions were iden- 
tified by 131] MIBG scintiscanning. None was pro- 
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spectively found by CT scanning, although one was 
suspected by the serendipitous appearance of a tu- 
mor blush during coronary angiography done for 
the evaluation of angina. It was further deter- 
mined, once middle mediastinal lesions could be lo- 
calized by 131I MIBG scintiscan, that augmented 
dynamic computer assisted tomography could pre- 
cisely define the anatomical site of the lesion. As 
experience with 131I MIBG scanning increased, the 
usefulness of combined localization modalities be- 
came more apparent. Composite scanning tech- 
niques using technetium and other agents to iden- 
tify kidneys, bone, and major blood vessels in con- 
junction with 131I MIBG have made preoperative 
localization even more accurate than previously 
achieved. 
The specificity of this test as well as its sensitiv- 
ity make it ideal for total body screening. Besides 
the adrenal medulla, uptake 3 hours after injection 
o f  131I MIBG is significant only in the thyroid [1]. 
Blockage of iodine uptake with Lugol's iodine mini- 
mizes uptake of 131I MIBG by the thyroid. 
The 10 patients with false-negative scans have 
brought attention to some technical points. First, 
cystic lesions may not be visualized with 131I 
MIBG. Second, lesions that cannot be seen with 
131I MIBG may be visualized with 123I MIBG since 
a larger dose may be given. The short half-life and 
greater cost of 123I as compared to 131I make its rou- 
tine use impractical. In difficult cases, however, it 
may prove to be the more sensitive agent. 
Although 90% of adrenal pheochromocytomas 
may be visualized using CT scanning, this is not the 
case with extra-adrenal and metastatic lesions. 
The success of 131I MIBG in localizing lesions 
not found by computed tomography proves it the 
better agent when metastatic lesions, small lesions, 
or extra-adrenal lesions are suspected. Pheo- 
chromocytomas as small as 0.5 cm in diameter 
have been visualized [2]. 
The extremely high incidence of malignancy in 
this series of patients reflects the selectivity of pa- 
tient referrals with malignant or occult pheo- 
chromocytomas because of the availability of 
MIBG as a scanning agent. There was a surpris- 
ingly high incidence of malignant extra-adrenal tu- 
mors found in this series (18 of 44 primary tu- 
mors). In most series, such tumors comprised no 
more than 10%. In a few cases, malignancy was 
first determined because of the extra-adrenal up- 
take of 131I MIBG in locations where chromaffin tis- 
sue should not normally be present. These lesions 
might have remained undetected for long periods of 
time without the use of this scanning agent. 
The number of patients thus far treated with 131I 
MIBG for unresectable and metastatic lesions is 
small but the results are promising. To date, sur- 
gical ablation is the mainstay of treatment. Chemo- 
therapeutic agents and radiation therapy have not 
been successful in arresting metastatic disease [8, 
9]. Until now, treatment of metastases that were 
not surgically resectable has been palliative. Alpha- 
methyl tyrosine, phenoxybenzamine, and in some 
cases beta adrenergic blocking drugs have been 
used. 131I MIBG is not blocked by phenoxybenz- 
amine. Consequently, patients may continue this 
drug during treatment with 131I MIBG. 
In conclusion, 131I MIBG scintigraphy is a safe, 
noninvasive diagnostic and therapeutic advance in 
the management of pheochromocytoma. It sup- 
plants other scintigraphic techniques for localiza- 
tion of pheochromocytomas and augments data ob- 
tained from computed tomography and angiogra- 
phy by providing functional as well as anatomic 
information. 
R6sum6 
De juin 1980 h ao0t 1983, 353 malades suspects 
d'6tre porteurs de ph6ochromocytomes ont 6t6 
soumis h la scintigraphie ~ l'iode marqu6: I TM m6ta- 
iodobenzylguanidine (I TM MIBG). Des ph6ochro- 
mocytomes extra-surr6naliens ont 6t6 d6couverts 
chez 15 des 18 sujets suspects d'6tre porteurs de 
telles 16sions extra-surr6naliennes, ce qui fut 
constat6 lors de l'intervention qui d6montra que les 
surr6nales 6taient normales. Les autres m6thodes 
conventionnelles n'avaient pas permis de localiser 
ces tumeurs dans la majorit6 des cas. Neuf des 
ph6ochromocytomes extra-surr6naliens furent 
d6couverts dans la partie moyenne du m6diastin. 
Ce groupe de tumeurs implique la mise en oeuvre 
de techniques particuli6res en plus du scanner pour 
localiser la tumeur. Ces explorations compl6men- 
taires permettent de planifier l'intervention chirur- 
gicale qui peut n6cessiter l'emploi d'une circula- 
tion extra-corporelle. Des ph6ochromocytomes 
extra-surr6naliens ont 6t6 d6couverts dans une 
famille qui ne prdsentait pas d'autres endocrinopa- 
thies. Les tumeurs chez 3 malades appartenant h 3 
g6n6rations diff6rentes si6geaient hors de la 
surr6nale et int6ressaient la veine cave. 
La scintigraphie h 1'I 131 marqu6 a permis de 
d6couvrir des mdtastases chez 40 malades porteurs 
d'un phdochromocytome malin, mais fut en d6faut 
dans 4 cas. Le diagnostic de ph6ochromocytome 
malin avec m6tastase fut port6 initialement chez 5 
malades. La scintigraphie ne se solda par aucun 
faux positif mais 10,5% de faux n6gatifs furent 
constatds chez 95 malades o/1 la pr6sence d'un 
ph6ochromocytome fut prouv6e par les donn6es 
biologiques ou opdratoires. 
Dix malades atteints de ph6ochromocytomes 
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malins ont 6t6 trait6s par 1'1 TM marqu6. Cinq 
d 'entre  eux accus~rent une diminution de volume 
de la tumeur  et des m6tastases et une diminution de 
la s6cr6tion des cat6cholamines. L ' iode marqu6: 
p31 m6ta-iodobenzylguanidine permet de d6celer 
les ph6ochromocytomes  qui 6chappent aux autres 
explorations. Le  fair qu'il s 'accumule 61ectivement 
au niveau de la tumeur permet  de penser  qu'il 
pourra  jouer  un r61e actif  dans le traitement de 
l 'affection. 
R e s u m e n  
E1 diagn6stico de feocromoci toma con frecuencia 
es m~ts simple que establecer la localizaci6n 
anat6mica del tumor,  lo cual es dificil, especialmen- 
te cuando el feocromoci toma es maligno, extra- 
adrenal o bilateral. Aproximadamente el 10% de los 
feocromoci tomas se origina en tejido cromafino 
ubicado en algt~n lugar entre la base del cr~ineo y la 
vejiga. La  tomograffa computadorizada de tercera 
generaci6n es extremadamente  precisa en la 
localizaci6n de lesiones intra-adrenales, pero no es 
muy t~til en la identificaci6n de feocromocitomas 
extra-adrenaleso metast~isicos. Hasta muy recien- 
temente no existfa modalidad alguna capaz de pro- 
veer  documentaci6n anat6mica y funcional del tu- 
mor con anterioridad a la intervenci6n quirtirgica. 
La  sfntesis de la I TM metayodo-benzilguanidina (I TM 
MIBG) ha hecho posible obtener  im~igenes 
scintigr~ificas de feocromocitomas y de tejido 
cromafino hiperpl~isico. 
Entre  junio de 1980 y agosto de 1983, scintigra- 
mas con 1131 MIBG fueron realizados en 353 pa- 
cientes con sospecha de feocromocitoma.  Se iden- 
tificaron feocromoci tomas extra-adrenales en 15 de 
18 pacientes quienes ulteriormente demonstraron 
tenet  tales tumores,  con gl~indulas suprarrenales nor- 
males. Los estudios convencionales de localiza- 
ci6n, con frecuencia realizados en forma repetida 
habfan fallado en casi todos los casos. Nueve de los 
feocromoci tomas extra-adrenales fueron hallados 
en el mediastino medio. Este grupo especial de 
tumores requiri6 estudios de localizaci6n adicion- 
ales con tomograffa computadorizada aumentada 
para el logro de la delineaci6n anat6mica 
especffica. Tales estudios complementarios hici- 
eron posible la planeaci6n precisa de la excisi6n 
quirt~rgica, la cual necesit6 circulaci6n extracor- 
p6rea en algunos casos. Feocromoci tomas extra- 
adrenales fueron identificados en una familia, la 
cuai no exhibi6 otras endocrinopatfas. Los tumo- 
res en 3 pacientes provenientes de 3 generaciones 
diferentes fueron todos de ubicaci6n peri-renal con 
compromiso de la vena cava. 
Los estudios con 1 TM MIBG detectaron lesiones 
metast~isicas en 40 pacientes con feocromocitomas 
malignos. En s61o 4 pacientes las metfistasis no 
pudieron ser fftcilmente demostradas.  E1 diagn6sti- 
co de feocromoci toma maligno y metasfftsico fue 
hecho en forma primaria por  la scintigraffa en 5 
pacientes. Los scintigramas con 1 TM MIBG no han 
dado resultados positivos falsos, en caso alguno, y 
han dado resultados negativos falsos en 10,5% de 
95 pacientes con feocromoci toma comprobado por 
evidencia bioqufmica o por  operaci6n. 
Diez pacientes han sido tratados para feocromo- 
citoma maligno con dosis terap6uticas de 1 TM 
MIBG. Cinco pacientes han manifestado respuesta 
objetiva con reducci6n del tamafio de las met~istasis 
o del tumor primario maligno con disminuci6n en la 
secreci6n de catecolaminas. 
Este agente ha demostrado ser de gran valor en 
la detecci6n de feocromoci tomas que han des- 
afiado todos los otros m6todos de localizaci6n. La  
1 TM MIBG se concentra  en la mayorfa de los feo- 
cromocitomas malignos, y los resultados prelimi- 
nares sugieren que habr~ de ser de gran utilidad en 
el tratamiento de esta enfermedad.  
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Invited Commentary 
Per-Ola Granberg, M.D., Ph.D. 
Department of Surgery, Karolinska Hospital. 
Stockholm. Sweden 
The use of 1311 metaiodobenzylguanidine (1311 
MIBG) in the localization and management of pheo- 
chromocytoma represents a major advance in the 
treatment of this disease. The preliminary results 
were presented in 1980 as a result of a long-term 
search for a suitable radiopharmaceutical agent. 
Since then a large clinical experience has been 
evaluated. To have studies on 95 patients with 
proven pheochromocytomas as well as 40 patients 
with malignant pheochromocytoma within a 3-year 
period is outstanding for one institution and will 
probably never be repeated. This fortunate oppor- 
tunity to evaluate the method is unique. The re- 
suits presented make it quite c lear that this method 
for localization of pheochromocytoma and for 
treatment of metastatic disease will be widely used 
in mosl centers of endocrine surgery. Particularly, 
the treatment of malignant disease is of great im-  
portance since other modalities apart from radical 
surgery have shown a low degree of efficacy. 
The place for 131I MIBG scan in the routine treat- 
ment of pheochromocytoma has still to be ascer- 
tained. The diagnosis of pheochromocytoma is pri- 
marily biochemical and, with the combination of a 
positive biochemical diagnosis and computed 
tomography showing an adrenal tumor, most of us 
proceed with surgical intervention. However, since 
roughly 10% of the lesions are extra-adrenal, a long 
transverse upper abdominal incision is mandatory. 
This approach gives access to both adrenals and 
permits exploration of the para-aortic regions and 
the perihilar renal zones as well. 
I have found the anterior approach hazardous in 
a few adequately blocked patients with right-sided 
adrenal pheochromocytoma and, therefore, I subs 
sequently preferred a posterolumbar incision. 131I 
MIBG scans offer a distinct advantage in this con- 
nection. In patients in whom the scan excludes 
multiple tumors, this surgical approach can be per- 
formed with better exposure of the adrenal, allow- 
ing a meticulous dissection and early ligation of 
larger veins--important details when handling 
these capricious neoplasms. 
